About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Almonertinib Plus Metronomic Oral Vinorelbine | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT05663177

Almonertinib Plus Metronomic Oral Vinorelbine

To evaluate the efficacy of continuing osimertinib in conjunction with metronomic oral vinorelbine after limited progression on osimertinib, to provide clinical experience on the treatment strategy fo...

Lead sponsor: Fujian Cancer Hospital•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Fujian Cancer Hospital

This study is a clinical observation study. The patients who comfirm the criteria will be treated with Almonertinib plus metronomic oral vinorelbine. The patients will be followed up until the tumor progressed, and the efficacy (PFS, ORR, DCR) of tumor therapy were evaluated. Drug administration regimen: Ametinib 110mg once a day; Oral Vinorelbine 40mg three times a week for three weeks and Q28d for one course.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Non-small cell lung cancer diagnosed by histopathology or cytology;
•Previous molecular pathology was EGFR sensitive mutation;
•Stage IV;
•ECOG score 0-2;
•Prior to receiving the third generation of EGFR-TKI targeted therapy, and TKI targeted therapy showed limited progress;
•According to RECIST1.1 standards, there are measurable or evaluable lesions
•The patient has fully understood this study and voluntarily signed a written informed consent form;
•The estimated survival time is more than 3 months.

Exclusion Criteria

•Histological or cytological confirmation of small cell lung cancer or squamous cell carcinoma at the first diagnosis;
•The progression of the third generation EGFR-TKI suggests histological transformation.

Related studies

RECRUITINGPhase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

NCT05967689 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Acute Effects of Visual Feedback-Assisted Inspiratory Muscle Training After Lobectomy

NCT07646288 · VATS, Respiratory Muscles, and more

RECRUITINGPhase 2

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

NCT07489066 · Carcinoma, Non-Small-Cell Lung, and more

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

NCT07369596 · Non Small Cell Lung Carcinoma NSCLC

A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC Patients: Real-World Experience in Taiwan (NEOREAL)

NCT07169708 · Non Small Cell Lung Cancer NSCLC

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 23, 2022Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment40

Start dateDec 2022

Last updatedDec 23, 2022

Condition

EGFR NSCLC Third-generation TKI

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 23, 2022Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions